Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Nilotinib
As low as
CHF 71.00
In stock
Only %1 left
SYN-1057-M0011 mgCHF 71.00
SYN-1057-M0055 mgCHF 99.00
SYN-1057-M01010 mgCHF 142.00
SYN-1057-M05050 mgCHF 213.00
SYN-1057-M100100 mgCHF 298.00
Specifications / Handling
| Product Details | |
|---|---|
| Synonyms | AMN107; Tasigna |
| Product Type | Chemical |
| Properties | |
| Formula | C28H22F3N7O |
| MW | 529.5 |
| CAS | 641571-10-0 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: Abl - PDGFR - BCR | Kinase Group: RTK, PTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | HHZIURLSWUIHRB-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| Safety Data Sheet |
Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Scientific Background Information
Product Description
Nilotinib is an orally bio-available aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor (IC(50) <30nM) with anti-neoplastic activity.
Product-specific References
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl: E. Weisberg, et al.; Cancer Cell. 7, 129 (2005)
You're in the Switzerland store. Not in Switzerland? Choose your country
You're in the Switzerland store (prices in CHF, shipping to Switzerland only). Ordering from another country? Please select it below.
Please note that not all products are available in every country store. Choose your country before starting the ordering process.
Country
Switzerland
United Kingdom
France
Germany
Austria
Italy
South Korea
United States
Argentina
Australia
Belgium
Bosnia and Herzegovina
Brazil
Canada
Chile
China
Colombia
Cyprus
Czech Republic
Denmark
Ecuador
Egypt
Estonia
Finland
Greece
Hong Kong
Hungary
India
Iran
Iraq
Ireland
Israel
Japan
Latvia
Lithuania
Luxembourg
Malaysia
Mexico
Netherlands
New Zealand
Norway
Pakistan
Peru
Poland
Portugal
Romania
Russia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Syria
Taiwan
Thailand
Turkey
Uruguay
Venezuela
Other Country
No country found




Download PDF